ArticleScientific reports2023
Prognostic utility and characterization of left ventricular hypertrophy using global thickness.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Associations of Metabolic Phenotypes with Cardiac Structure and Clinical Outcomes: Insights from the UK Biobank.The Journal of clinical endocrinology and metabolism · 2026Article
- Prognostic value of left ventricular phenotypes by cardiac magnetic resonance in elderly and non-elderly patients.Journal of geriatric cardiology : JGC · 2026Article
- Global Myocardial Wall Thickness in Transfusion-Dependent Thalassemia: A Cross-Sectional MRI Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Deep Learning-Based Algorithm for the Classification of Left Ventricle Segments by Hypertrophy Severity.Journal of imaging · 2025Article
- Left ventricular wall thickness heterogeneity improves cardiovascular disease diagnosis and prognosis: a UK Biobank cardiovascular magnetic resonance cohort study.European heart journal. Imaging methods and practice · 2025Article
- Lung water density is increased in patients at risk of heart failure and is largely independent of conventional cardiovascular magnetic resonance measures.European heart journal. Imaging methods and practice · 2024Article
- Challenges in Echocardiography for the Diagnosis and Prognosis of Non-Ischemic Hypertensive Heart Disease.Journal of clinical medicine · 2024Review
- Cardiac remodeling in elite young Asian female soccer players.Frontiers in cardiovascular medicine · 2024Article
- Hydraulic forces assist left ventricular filling in aortic stenosis at baseline and after valve replacement.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic ResonanceObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Cardiovascular magnetic resonance (CMR) can accurately measure left ventricular (LV) mass, and several measures related to LV wall thickness exist. We hypothesized that prognosis can be used to select an optimal measure of wall thickness for characterizing LV hypertrophy. Subjects having undergone CMR were studied (cardiac patients, n = 2543; healthy volunteers, n = 100). A new measure, global wall thickness (GT, GTI if indexed to body surface area) was accurately calculated from LV mass and end-diastolic volume. Among patients with follow-up (n = 1575, median follow-up 5.4 years), the most predictive measure of death or hospitalization for heart failure was LV mass index (LVMI) (hazard ratio (HR)[95% confidence interval] 1.16[1.12-1.20], p < 0.001), followed by GTI (HR 1.14[1.09-1.19], p < 0.001). Among patients with normal findings (n = 326, median follow-up 5.8 years), the most predictive measure was GT (HR 1.62[1.35-1.94], p < 0.001). GT and LVMI could characterize patients as having a normal LV mass and wall thickness, concentric remodeling, concentric hypertrophy, or eccentric hypertrophy, and the three abnormal groups had worse prognosis than the normal group (p < 0.05 for all). LV mass is highly prognostic when mass is elevated, but GT is easily and accurately calculated, and adds value and discrimination amongst those with normal LV mass (early disease).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.